CRISPR-Cas9 gene editing and its therapeutic applications: A literature review

Authors

DOI:

https://doi.org/10.33448/rsd-v13i8.46681

Keywords:

Gene editing; CRISPR-Cas9; Genetic therapies.

Abstract

The CRISPR-Cas9 technology has revolutionized biotechnology and medicine, offering new possibilities for the treatment of genetic and infectious diseases. This study aims to review the literature on the therapeutic applications of CRISPR-Cas9, highlighting advances, challenges, and future perspectives. The methodology used was a narrative literature review, with research conducted in the databases Google Scholar, LILACS, and SCIELO, covering articles published between 2000 and 2024 in Portuguese, English, and Spanish. The results indicate that CRISPR-Cas9 has shown great potential in preclinical and clinical studies. In animal models, the technology was effective in correcting genetic mutations responsible for diseases such as Duchenne muscular dystrophy and type I tyrosinemia. Initial clinical studies also demonstrated success in modifying T cells to treat hematological cancers and viral infections such as HIV. However, significant challenges remain, including the need to improve the specificity of genetic editing and delivery efficiency, as well as addressing ethical and safety issues. The conclusion highlights that despite the challenges, CRISPR-Cas9 has the potential to transform medicine and significantly improve patients' quality of life. Continuous research and interdisciplinary collaboration are essential to overcome these challenges. Proper regulation and effective communication with the public are also crucial to ensure that CRISPR-Cas9-based therapies are developed and implemented safely and ethically. With these efforts, CRISPR-Cas9 can lead to significant advances in human health, providing more effective and personalized treatments.

References

Baltimore, D., Berg, P., Botchan, M., Carroll, D., Charo, R. A., Church, G., & Greely, H. T. (2015). A prudent path forward for genomic engineering and germline gene modification. Science, 348(6230), 36-38.

Barrangou, R., & Doudna, J. A. (2016). Applications of CRISPR technologies in research and beyond. Nature Biotechnology, 34(9), 933-941.

Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., & Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. Science, 339(6121), 819-823.

Cyranoski, D. (2016). CRISPR gene-editing tested in a person for the first time. Nature News, 539(7630), 479.

Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.

Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31(9), 822-826.

Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157(6), 1262-1278.

Jasanoff, S., Hurlbut, J. B., & Saha, K. (2015). CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology, 32(1), 25-32.

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science, 337(6096), 816-821.

Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H. R., & Kim, J. S. (2014). Digenome-seq: Genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. Nature Methods, 12(3), 237-243.

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420-424.

Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015). Don't edit the human germ line. Nature News, 519(7544), 410.

Ledford, H. (2015). CRISPR, the disruptor. Nature News, 522(7554), 20.

Liu, Z., Chen, S., Jin, X., Wang, Q., Yang, K., Li, C., & Liang, P. (2017). Genome editing of CCR5 by AsCpf1 renders CD4+ T cells resistance to HIV-1 infection. Cell & Bioscience, 7(1), 47.

Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2016). Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA. Science, 345(6201), 1184-1188.

Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., & Nureki, O. (2014). Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 156(5), 935-949.

Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., & June, C. H. (2020). CRISPR-engineered T cells in patients with refractory cancer. Science, 367(6481), eaba7365.

Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2016). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 153(4), 910-918.

Yin, H., Song, C. Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., & Anderson, D. G. (2014). Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nature Biotechnology, 32(6), 551-553.

Zhang, X. H., Tee, L. Y., Wang, X. G., Huang, Q. S., & Yang, S. H. (2015). Off-target effects in CRISPR/Cas9-mediated genome engineering. Molecular Therapy - Nucleic Acids, 4, e264.

Downloads

Published

29/08/2024

How to Cite

MENDES, L. M. C. .; LINO, L. A. .; BORDIGNON , T. M.; CASTRO, M. M. de .; BARTHOLOMEU, L. M. D. de O. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .; ALMEIDA, R. Z. S. de .; CARNEIRO, I. M. V. .; SILVA, I. M. da .; MARTINS, I. D. R. .; HONORATO , M. P. P. .; ANTERO , A. C. de A. .; COLARES, G. L. G. S. .; PEREIRA , B. R. . CRISPR-Cas9 gene editing and its therapeutic applications: A literature review. Research, Society and Development, [S. l.], v. 13, n. 8, p. e11513846681, 2024. DOI: 10.33448/rsd-v13i8.46681. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/46681. Acesso em: 6 sep. 2024.

Issue

Vol. 13 No. 8

Section

Health Sciences

License

Copyright (c) 2024 Luis Miguel Carvalho Mendes; Lucas Arruda Lino; Tarciana Maria Bordignon ; Marvio Moreira de Castro; Lorrayne Michelle Dantas de Oliveira Bartholomeu; R Zaine Santos de Almeida; Ingrid Maria Veloso Carneiro; Izabel Mendes da Silva; Ingrid Dara Ribeiro Martins; Maria Paula Pereira Honorato ; Ana Cristina de Aquino Antero ; Gabriel Lucas Galvan Soares Colares; Bruna Rocha Pereira

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.